Efficacy and local safety of a calcipotriol/betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris

European Journal of Dermatology

Volumn 15, Issue 1, 2005, Pages 37-39

  Parslew, Richard ^a   Traulsen, Jette ^b  

^a R Liverpool Broadgreen Univ H T   (United Kingdom)

^b LEO PHARMA A S   (Denmark)

Author keywords

Betamethasone dipropionate; Calcipotriol; Geriatric; Psoriasis therapy

Indexed keywords

BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL;

AGING; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GERIATRICS; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PSORIASIS VULGARIS; PURPURA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN ATROPHY; TELANGIECTASIA;

ADULT; AGE FACTORS; AGED; BETAMETHASONE; CALCITRIOL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PSORIASIS;

EID: 13844251899     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. National Projections Program. Projected resident population of the United States as of July 1, 2025, Middle Series. US Census Bureau, 2002.
2. Eurostat. Regional population ageing of the EU at different speeds up to 2025, in Statistics in Focus. In: Eurostat. 1999: 1-8.
3. Ritter J, Lewis L, Mant T. In: Ritter J, ed. A textbook of clinical pharmacology. London: Hodder Arnold, 1994: 731.
4. Yosipovitch G, Tang M. Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options. Drugs Aging 2002; 19(11): 847-63.
5. Bonifati C, Carducci M, Mussi A, D'Auria L. Recognition and treatment of psoriasis: special considerations in elderly patients. Drugs Aging 1998; 12(3): 177-90.
6. Ortonne J, Kaufmann R, Lecha M, Goodfield M. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology. 2004; In press.
7. Papp K, Guenther L, Boyden B, Larsen F, Harvima R, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003; 48(1): 48-54.
8. Douglas W, Poulin Y, Decroix J, Ortonne J, Mrowietz U, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionote or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002; 82(2): 131-5.
9. Guenther L, Cambazard F, Van de Kerkhof P, Snellman E, Kragballe K, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgoris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002; 147(2): 316-23.
10. Kragballe K, Noerrelund K, Lui H, Ortonne J, Wozel G, et al. Efficacy of once daily treatment regimens with calcipotriol/ betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004; 150(6): 1167-73.
11. Kaufmann R, Bibby A, Bissonnette R, Cambazard F, Chu A, et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205(4): 389-93.